| Particulars (Rupees in Crores.) | Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 |
|---|---|---|---|---|---|
Gross Sales | 5,276.3 | 4,898.4 | 4,558.4 | 4,544.73 | 4,412.19 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 5,276.3 | 4,898.4 | 4,558.4 | 4,544.73 | 4,412.19 |
Other Operating Income | 29.4 | 45.9 | 45.3 | 57.9 | 106.57 |
Other Income | 407.7 | 75 | 33.9 | 14.25 | 231.73 |
Total Income | 5,713.4 | 5,019.3 | 4,637.6 | 4,616.88 | 4,750.49 |
Total Expenditure | 4,477.8 | 4,314.9 | 4,108 | 3,704.97 | 3,510.9 |
PBIDT | 1,235.6 | 704.4 | 529.6 | 911.91 | 1,239.59 |
Interest | 187.6 | 199.3 | 132.6 | 105.98 | 140.76 |
PBDT | 1,048 | 505.1 | 397 | 805.93 | 1,098.83 |
Depreciation | 273.4 | 280.9 | 282.8 | 281.15 | 262.71 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 98.4 | 94.5 | 127.9 | 131.68 | 163.79 |
Deferred Tax | -8.8 | -4.8 | -49.3 | 39.17 | 50.37 |
Reported Profit After Tax | 685 | 134.5 | 35.6 | 353.93 | 621.96 |
Minority Interest After NP | -0.8 | -1.2 | -1.3 | -0.46 | -0.01 |
Net Profit after Minority Interest | 685.8 | 135.7 | 36.9 | 354.39 | 621.97 |
Extra-ordinary Items | 316.71 | 0 | 6.81 | 0 | -7.1 |
Adjusted Profit After Extra-ordinary item | 369.09 | 135.7 | 30.09 | 354.39 | 629.07 |
EPS (Unit Curr.) | 43.28 | 8.56 | 2.32 | 22.26 | 39.05 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 15.8 | 15.8 | 15.8 | 15.92 | 15.93 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 23.41 | 14.38 | 11.61 | 20.06 | 28.09 |
PBDTM(%) | 19.86 | 10.31 | 8.7 | 17.73 | 24.9 |
PATM(%) | 12.98 | 2.74 | 0.78 | 7.78 | 14.09 |
This FDA audit confirms compliance with regulatory standards, enhancing the credibility of Jubilant's operations in the United States.
Jubilant Pharmova Ltd has gained a total of 126% in the last one year, and almost 75% gain since the beginning of the year.
Here are some of the stocks that may see significant price movement today: Tata Motors, Reliance Industries, IREDA, etc.
Drug company Jubilant Pharmova Ltd will acquire an 80% stake in Pierre Fabre Laboratories' Research & Development Centre in Saint Julien, France.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
